Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNDNASDAQ:PCVXNYSE:QGENNASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$157.94-0.2%$143.63$111.09▼$169.37$9.59B0.62459,473 shs264,856 shsPCVXVaxcyte$70.77+3.2%$80.72$58.10▼$121.06$9.11B1.02940,197 shs899,353 shsQGENQiagen$39.65+0.2%$40.92$37.63▼$49.30$8.80B0.441.02 million shs655,924 shsRXRXRecursion Pharmaceuticals$5.97-3.2%$7.47$5.60▼$12.36$2.40B0.8510.66 million shs14.68 million shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-1.71%-4.68%+4.78%+12.81%+5.55%PCVXVaxcyte-4.65%-9.96%-16.06%-20.07%+1.69%QGENQiagen-0.27%-0.14%-0.86%-9.55%-4.65%RXRXRecursion Pharmaceuticals-5.51%-6.23%-31.44%-19.45%-40.21%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S2.9959 of 5 stars4.51.00.00.03.01.70.6PCVXVaxcyte2.0593 of 5 stars3.50.00.00.03.92.50.0QGENQiagen3.5087 of 5 stars2.23.00.04.51.41.71.3RXRXRecursion Pharmaceuticals2.2164 of 5 stars3.22.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.93Moderate Buy$204.6429.57% UpsidePCVXVaxcyte 3.00Buy$147.50108.42% UpsideQGENQiagen 2.30Hold$47.7120.32% UpsideRXRXRecursion Pharmaceuticals 2.40Hold$8.2538.19% UpsideCurrent Analyst Ratings BreakdownLatest RXRX, ASND, PCVX, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$168.00 ➝ $200.003/12/2025PCVXVaxcyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$160.00 ➝ $160.002/28/2025RXRXRecursion PharmaceuticalsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/28/2025RXRXRecursion PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$7.00 ➝ $6.002/26/2025PCVXVaxcyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$160.00 ➝ $160.002/26/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $140.002/25/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$170.00 ➝ $200.002/19/2025QGENQiagenBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold2/19/2025QGENQiagenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$52.00 ➝ $42.002/18/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$180.002/18/2025ASNDAscendis Pharma A/SEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$220.00 ➝ $260.00(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$363.64M26.36N/AN/A($1.88) per share-84.01PCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/AQGENQiagen$1.98B4.45$3.30 per share12.01$16.08 per share2.47RXRXRecursion Pharmaceuticals$58.49M41.03N/AN/A$1.98 per share3.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$7.10N/A658.08N/A-104.54%N/A-39.23%5/1/2025 (Estimated)PCVXVaxcyte-$402.27M-$3.80N/AN/AN/AN/A-23.53%-22.20%5/6/2025 (Estimated)QGENQiagen$83.59M$0.36110.4116.122.394.23%13.92%8.40%5/5/2025 (Estimated)RXRXRecursion Pharmaceuticals-$328.07M-$1.66N/AN/AN/A-579.52%-76.56%-55.68%5/8/2025 (Estimated)Latest RXRX, ASND, PCVX, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2025Q4 2024RXRXRecursion Pharmaceuticals-$0.36-$0.53-$0.17-$0.53$19.04 million$4.60 million2/25/2025Q4 2024PCVXVaxcyte-$1.16-$1.02+$0.14-$1.02N/AN/A2/12/2025Q4 2024ASNDAscendis Pharma A/S-$1.32-$0.68+$0.64-$0.68$115.06 millionN/A2/5/2025Q4 2024QGENQiagen$0.60$0.61+$0.01$0.39$518.54 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/AQGENQiagenN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.170.84PCVXVaxcyteN/A17.8817.88QGENQiagen0.383.613.09RXRXRecursion Pharmaceuticals0.044.354.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/APCVXVaxcyte96.78%QGENQiagen70.00%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%PCVXVaxcyte3.10%QGENQiagen9.00%RXRXRecursion Pharmaceuticals15.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01760.69 million36.41 millionOptionablePCVXVaxcyte160128.76 million120.77 millionOptionableQGENQiagen6,030221.86 million201.89 millionOptionableRXRXRecursion Pharmaceuticals400401.99 million329.18 millionOptionableRXRX, ASND, PCVX, and QGEN HeadlinesRecent News About These CompaniesRecursion: A Look At Near-Term Phase 1b And Phase 2 CatalystsMarch 27 at 11:30 AM | seekingalpha.comSwiss National Bank Grows Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)March 27 at 3:29 AM | marketbeat.comIs Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?March 26 at 2:06 PM | msn.comWhy Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday?March 26 at 9:04 AM | msn.comCathie Wood’s ARK Investment buys 205K shares of Recursion Pharmaceuticals todayMarch 26 at 4:03 AM | markets.businessinsider.comCathie Wood’s ARK Investment buys 161K shares of Recursion Pharmaceuticals todayMarch 21, 2025 | markets.businessinsider.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Charles Schwab Investment Management Inc.March 21, 2025 | marketbeat.comWhy Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market TodayMarch 20, 2025 | zacks.comPrivium Fund Management B.V. Purchases 41,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)March 20, 2025 | marketbeat.comPlatinum Investment Management Ltd. Acquires 546,929 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)March 20, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Here's WhyMarch 19, 2025 | marketbeat.comRecursion appoints Namandje Bumpus, Elaine Sun to boardMarch 18, 2025 | markets.businessinsider.comRecursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity OfferingMarch 18, 2025 | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 4.5% - What's Next?March 18, 2025 | marketbeat.comWhy Recursion Pharmaceuticals (RXRX) Went Up on Monday?March 18, 2025 | insidermonkey.comRecursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?March 18, 2025 | zacks.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Nikko Asset Management Americas Inc.March 18, 2025 | marketbeat.comWhich Is a Better Investment, Recursion Pharmaceuticals, Inc. or Zai Lab Limited Stock?March 17, 2025 | aaii.com6RXRX : Recursion Pharmaceuticals's Options: A Look at...March 17, 2025 | benzinga.comBank of New York Mellon Corp Has $5.75 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)March 17, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 4.6% - Still a Buy?March 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRXRX, ASND, PCVX, and QGEN Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$157.94 -0.34 (-0.21%) Closing price 04:00 PM EasternExtended Trading$160.55 +2.61 (+1.65%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Vaxcyte NASDAQ:PCVX$70.77 +2.21 (+3.22%) Closing price 04:00 PM EasternExtended Trading$70.83 +0.06 (+0.08%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Qiagen NYSE:QGEN$39.65 +0.07 (+0.18%) Closing price 03:59 PM EasternExtended Trading$39.65 0.00 (0.00%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Recursion Pharmaceuticals NASDAQ:RXRX$5.97 -0.20 (-3.24%) Closing price 04:00 PM EasternExtended Trading$6.02 +0.05 (+0.84%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Intel's Strategy to Win the Next AI Frontier Is Alphabet Too Cheap to Ignore After Its Recent Correction? Qualcomm Stock Is Coiling for a Breakout Tesla Stock: Has the Mother of All Comebacks Begun? Fortinet: A Top Cybersecurity Stock With Growth Catalysts Energy Transfer: Powering Data With Dividends and Diversification Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
